About Us

Management

Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Chief Executive Officer and Founder

Stephan Oehen

Chief Operating Officer
and Founder

Philippe Lievre

Chief Business Officer
and Founder

Brice Suire

Chief Financial Officer and Founder

Our supervisory board is composed of venture capital leaders from leading international venture funds, also joined by Dr. Dhaval Patel, leader in S1Pr drug developments (Gilenya).

Manus Rogan

Chair
Read more

Dhaval Patel

Director
Read more

Marten Steen

Director
Read more

Henry Skinner

Director
Read more

Lionel Carnot

Director
Read more

Advisory Board

Christoph Bucher

Head of Clinical Advisory Board and Founder

Simone Seiter

Head of Commercial and Scientific Advisory Board and Founder

Stephan Oehen

Chief Operating Officer and Founder

Immunologist, PhD with 21 years experience in biotech and pharma, a strong science (University Basel, University Hospital Zürich, UC San Diego), and drug development background in Autoimmunity, Transplantation and Inflammation (ATI). Stephan has an expert track record in Program Management and held several leadership positions in biotech (Cytos Biotechnology) and big pharma (Novartis Pharma). In 2006 he joined Novartis Research (NIBR) holding positions as Project Management Director ATI and Therapeutic Area Head of the Project Management Office. In his roles he managed the KRP203 program from inception to today. In 2018, he moved to Novartis Global Drug Development (Global Health) as Global Program Director (GPD) for out-partnering and as GPD of the Transplant Global Program Team.

Philippe Lievre

Chief Business Officer and Founder

A UK Pharmacist with an MBA from Temple University. Philippe started his career at Warner -Lambert and went on to Rhone-Poulenc as Director of Pharmaceutical Affairs of the Joint-Venture created with Tanabe Seiyaku. A few years later, Philippe created Tanabe Pharma in Paris and ultimately relocated to Osaka as Deputy General Manager in the Licensing and Business Department of Tanabe. Philippe joined Novartis in 2002, initially as a Marketing Manager (Transplantation Unit) in Tokyo, and later joined Novartis in Basel as an Alliance Manager for the Neuroscience Franchise. Philippe returned to Japan in 2014 to lead and reshape the Novartis Japanese BD&L organization. In 2017, Philippe joined the Basel BD&L group to head the Global Pharma Alliance Management Team. He has successfully managed many major in-licensing transactions.

Brice Suire

Chief Financial Officer and Founder

Brice has over 25 years’ financial experience in the life science sector, having worked as CFO and Financial consultant for several biotech and medtech companies including Gensight, Vivet and Oculis. Before that he worked for over 15 years at Novartis in Finance positions of increasing responsibility, including as Global Head of Finance Supply Chain Pharma. Prior to that, Brice played a significant role in establishing the Novartis Institute for Biomedical Research in Cambridge, MA, where he worked as Head of Finance for Research Collaborations and Global Head of Financial Reporting and Accounting for Research (at 6 different Novartis sites). Brice started his career with Audit Consultancy firms Mazars in Paris and London and Price Waterhouse Coopers in Madrid. He has a Master’s in Finance from Paris Dauphine, CPA, an IEP from INSEAD, and completed the Novartis Harvard Finance Leadership Program at Harvard Business School.

Dhaval Patel

Director

Dhaval is an EVP and CSO of UCB, based in Brussels, Belgium. He received an MD and PhD (Microbiology and Immunology) from and further clinical training in Internal Medicine, Rheumatology, Allergy, and Clinical Immunology at Duke University. Prior to joining the industry in 2006, he was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. During a 10 year career at Novartis, he led Research in Europe and Autoimmunity, Transplantation and Inflammation Disease Area which developed the S1PR modulators fingolimid and siponimod as well as several other medicines. He was also an Entrepreneur in Residence at the Novartis Venture Fund, and serves on several biotechnology boards.

Marten Steen

Director

Dr. Mårten Steen. Partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology licensing. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry. He is the author of numerous scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.

Henry Skinner

Director

Dr. Skinner is Senior Vice President, Venture at Tekla Capital Management. Prior to joining Tekla, Dr. Skinner Served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.

Lionel Carnot

Director

Lionel Carnot is a Partner at Earlybird. Before joining Earlybird in 2016, Lionel was a Managing Director at Bay City Capital after having been extensively involved in the firm’s activities as part of The Pritzker Organization. Prior to The Pritzker Organization, Lionel was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly and several sales and marketing positions at Sanofi-Aventis. He was also a strategy and management consultant to the biopharmaceutical industry at Booz Allen & Hamilton, and Accenture Strategic Services. Lionel holds an MBA with Distinction from INSEAD and an M.Sc. in Molecular Biology from the University of Geneva.

Simone Seiter

Head of Commercial and Scientific Advisory Board and Founder

Simone is a Partner at Simon-Kucher & Partners, leading their Commercial Strategy Cluster within the Life Sciences division. Before joining the company, she was the global lead of IQVIA´s Brand & Commercial Strategy Team and lead their launch excellence platform. She is a board certified dermatologists and worked at the University hospitals in Heidelberg and Homburg in Germany, as well as at several dermatology clinics. She also worked as a postdoctoral fellow at the NIH. Simone specializes in strategic pharmaceutical commercialization, launch, and brand excellence, portfolio and lifecycle management, including go-to-market strategies, P&MA strategies, product lifecycle strategies, and orphan diseases. She has supported many of the current top 20 pharma companies in successfully developing and commercializing their healthcare innovations in Europe and the US. Simone has published a number of articles and white papers on launch excellence and coauthored the IQVIA Launch Excellence series.

About Us

Management

Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Stephan Oehen

Philippe Lievre

Brice Suire

Supervisory Board

Our supervisory board is composed of venture capital leaders from leading international venture funds, also joined by Dr. Dhaval Patel, leader in S1Pr drug developments (Gilenya).

Manus Rogan

Dhaval Patel

Marten Steen

Henry Skinner

Lionel Carnot

Advisory Board

Christoph Bucher

Simone Seiter

Investors Funds

Contact Us

Priothera Ltd

Priothera SAS France

Stephan Oehen

Chief Operating Officer and Founder

Philippe Lievre

Chief Business Officer and Founder

Brice Suire

Chief Financial Officer and Founder

Dhaval Patel

Director

Marten Steen

Director

Henry Skinner

Director

Lionel Carnot

Director

Simone Seiter

Head of Commercial and Scientific Advisory Board and Founder